501 related articles for article (PubMed ID: 36202997)
1. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
Chalkias S; Eder F; Essink B; Khetan S; Nestorova B; Feng J; Chen X; Chang Y; Zhou H; Montefiori D; Edwards DK; Girard B; Pajon R; Dutko FJ; Leav B; Walsh SR; Baden LR; Miller JM; Das R
Nat Med; 2022 Nov; 28(11):2388-2397. PubMed ID: 36202997
[TBL] [Abstract][Full Text] [Related]
2. A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
Chalkias S; Harper C; Vrbicky K; Walsh SR; Essink B; Brosz A; McGhee N; Tomassini JE; Chen X; Chang Y; Sutherland A; Montefiori DC; Girard B; Edwards DK; Feng J; Zhou H; Baden LR; Miller JM; Das R
N Engl J Med; 2022 Oct; 387(14):1279-1291. PubMed ID: 36112399
[TBL] [Abstract][Full Text] [Related]
3. Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
Dixit A; Bennett R; Ali K; Griffin C; Clifford RA; Turner M; Poston R; Hautzinger K; Yeakey A; Girard B; Zhou W; Deng W; Zhou H; Schnyder Ghamloush S; Kuter BJ; Slobod K; Miller JM; Priddy F; Das R;
Lancet Infect Dis; 2024 Jul; 24(7):687-697. PubMed ID: 38518789
[TBL] [Abstract][Full Text] [Related]
4. Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19.
Chalkias S; Harper C; Vrbicky K; Walsh SR; Essink B; Brosz A; McGhee N; Tomassini JE; Chen X; Ying Chang ; Sutherland A; Montefiori DC; Girard B; Edwards DK; Jing Feng ; Zhou H; Baden LR; Miller JM; Das R
Nat Commun; 2023 Aug; 14(1):5125. PubMed ID: 37612300
[TBL] [Abstract][Full Text] [Related]
5. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
Lee IT; Cosgrove CA; Moore P; Bethune C; Nally R; Bula M; Kalra PA; Clark R; Dargan PI; Boffito M; Sheridan R; Moran E; Darton TC; Burns F; Saralaya D; Duncan CJA; Lillie PJ; San Francisco Ramos A; Galiza EP; Heath PT; Girard B; Parker C; Rust D; Mehta S; de Windt E; Sutherland A; Tomassini JE; Dutko FJ; Chalkias S; Deng W; Chen X; Feng J; Tracy L; Zhou H; Miller JM; Das R;
Lancet Infect Dis; 2023 Sep; 23(9):1007-1019. PubMed ID: 37348519
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
Bennett C; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; McCallum Pardey TG; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM;
Lancet Infect Dis; 2024 Jun; 24(6):581-593. PubMed ID: 38460525
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
[TBL] [Abstract][Full Text] [Related]
8. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.
Chu L; Vrbicky K; Montefiori D; Huang W; Nestorova B; Chang Y; Carfi A; Edwards DK; Oestreicher J; Legault H; Dutko FJ; Girard B; Pajon R; Miller JM; Das R; Leav B; McPhee R
Nat Med; 2022 May; 28(5):1042-1049. PubMed ID: 35241844
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
Tan NH; Geers D; Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Boerma A; Nijhof SH; van Dort KA; Koopmans MPG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; van Baarle D; Zaeck LM; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
Lancet Infect Dis; 2023 Aug; 23(8):901-913. PubMed ID: 37088096
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.
Salehi M; Alavi Darazam I; Nematollahi A; Alimohammadi M; Pouya S; Alimohammadi R; Khajavirad N; Porgoo M; Sedghi M; Mahdi Sepahi M; Azimi M; Hosseini H; Mahmoud Hashemi S; Dehghanizadeh S; Khoddami V
Int Immunopharmacol; 2024 Jun; 134():112192. PubMed ID: 38761778
[TBL] [Abstract][Full Text] [Related]
11. Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results.
Chalkias S; Whatley JL; Eder F; Essink B; Khetan S; Bradley P; Brosz A; McGhee N; Tomassini JE; Chen X; Zhao X; Sutherland A; Shen X; Girard B; Edwards DK; Feng J; Zhou H; Walsh S; Montefiori DC; Baden LR; Miller JM; Das R
Nat Med; 2023 Sep; 29(9):2325-2333. PubMed ID: 37653342
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
[TBL] [Abstract][Full Text] [Related]
13. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
Scheaffer SM; Lee D; Whitener B; Ying B; Wu K; Liang CY; Jani H; Martin P; Amato NJ; Avena LE; Berrueta DM; Schmidt SD; O'Dell S; Nasir A; Chuang GY; Stewart-Jones G; Koup RA; Doria-Rose NA; Carfi A; Elbashir SM; Thackray LB; Edwards DK; Diamond MS
Nat Med; 2023 Jan; 29(1):247-257. PubMed ID: 36265510
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.
Ji Y; Sui X; Miao W; Wang C; Wang Q; Duan Z; Wei B; Wu D; Wei M; Shao J; Zheng X; Zhu T
Vaccine; 2024 Feb; 42(6):1292-1299. PubMed ID: 38296705
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial.
Hannawi S; Saifeldin L; Abuquta A; Alamadi A; Mahmoud SA; Hassan A; Liu D; Yan L; Xie L
EBioMedicine; 2023 Jan; 87():104386. PubMed ID: 36470077
[TBL] [Abstract][Full Text] [Related]
16. Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines.
Chalkias S; McGhee N; Whatley JL; Essink B; Brosz A; Tomassini JE; Girard B; Edwards DK; Wu K; Nasir A; Lee D; Avena LE; Feng J; Deng W; Montefiori DC; Baden LR; Miller JM; Das R
J Infect Dis; 2024 Feb; ():. PubMed ID: 38349280
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.
Choi A; Koch M; Wu K; Chu L; Ma L; Hill A; Nunna N; Huang W; Oestreicher J; Colpitts T; Bennett H; Legault H; Paila Y; Nestorova B; Ding B; Montefiori D; Pajon R; Miller JM; Leav B; Carfi A; McPhee R; Edwards DK
Nat Med; 2021 Nov; 27(11):2025-2031. PubMed ID: 34526698
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
[TBL] [Abstract][Full Text] [Related]
19. The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.
Zhou C; Qiu Y; Wang J; Zhong X; Zhu X; Huang X; Yang L; Ji Q; Zhou F; Wu S; Yang M; Zhang J; Liu K; Ji L; Yang H; Li C; Zhao Y
Emerg Microbes Infect; 2024 Dec; 13(1):2320913. PubMed ID: 38860446
[TBL] [Abstract][Full Text] [Related]
20. Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).
Chalkias S; Schwartz H; Nestorova B; Feng J; Chang Y; Zhou H; Dutko FJ; Edwards DK; Montefiori D; Pajon R; Leav B; Miller JM; Das R
medRxiv; 2022 Mar; ():. PubMed ID: 35291289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
